about
Haloperidol prophylaxis in critically ill patients with a high risk for deliriumPsychotropic drugs and the ECG: focus on the QTc interval.Detecting potential adverse reactions of sulpiride in schizophrenic patients by prescription sequence symmetry analysisThe dog's role in the preclinical assessment of QT interval prolongation.Clinical relevance and management of drug-related QT interval prolongation.Torsade de pointes associated with the administration of intravenous haloperidol:a review of the literature and practical guidelines for use.Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics.Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism.A systematic review of cardiovascular effects after atypical antipsychotic medication overdose.Drug-induced QT-interval prolongation: considerations for clinicians.Analytic reviews: managing the agitated patient in the ICU: sedation, analgesia, and neuromuscular blockade.Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidol.Prevention of ICU delirium and delirium-related outcome with haloperidol: a study protocol for a multicenter randomized controlled trial.A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients.Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.
P2860
Q33750794-BCDFDF65-D5CC-4857-9D70-CCC4072519E9Q34628573-7E8A9B60-DDF9-4AAB-8C8F-33F99484615FQ34660087-C395058E-B6FA-4306-B4D8-A3A5DB439BF8Q35070458-BC2303F3-8D0A-4897-B46F-1663E86B378FQ35186542-BFD85640-209F-45A5-A56D-64D73D53783CQ35570977-FA7D1121-7F90-4B82-BE4C-EA9559745E15Q36048792-FD6C8213-5D68-4932-8225-485D6F32B65FQ36725206-4A3DD325-F6BC-4268-8427-7F491FCD8031Q37381004-53D4CDAB-9CE8-4712-80BE-921DC4A63DA5Q37767425-0BFD15B9-49B6-42B9-BA94-FFD74CB6B8CEQ37776069-16D4187C-D57F-48A7-90D7-403443FD2195Q40900114-7D5DC935-D844-4AF3-82AB-AAE2737B931AQ41894968-74CD235D-464D-4AFA-8418-775153D07EAFQ46028189-4E07A09E-D82F-4996-9EA7-9F70D8643322Q51331734-4A9D91BC-C706-4388-9F1E-510FFD79188E
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Haloperidol-induced torsade de pointes
@ast
Haloperidol-induced torsade de pointes
@en
Haloperidol-induced torsade de pointes
@nl
type
label
Haloperidol-induced torsade de pointes
@ast
Haloperidol-induced torsade de pointes
@en
Haloperidol-induced torsade de pointes
@nl
prefLabel
Haloperidol-induced torsade de pointes
@ast
Haloperidol-induced torsade de pointes
@en
Haloperidol-induced torsade de pointes
@nl
P2093
P2860
P356
P1476
Haloperidol-induced torsade de pointes
@en
P2093
J M O'Brien
R P Rockwood
P2860
P304
P356
10.1345/APH.19017
P407
P577
1999-10-01T00:00:00Z